A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study To Compare Safety and Pharmacokinetic Properties of CJ-30044 and Bepotastine Besilate and To Investigate Food-effect on Pharmacokinetics of CJ-30044 in Healthy Adult Male Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

May 31, 2013

Conditions

Healthy

Interventions

DRUG

CJ-30044

20.51mg a day,PO,QD

DRUG

TALION TAB. 10mg

10mg a day,PO,BID

Trial Locations (1)

Yonsei university severance hospital, Seoul